Oral Coronavirus Vaccine
A Potential Temperature Stable, Oral Vaccine for COVID-19
Potential application across multiple coronavirus types, including COVID-19 (SARS-CoV-2)
Orally active live-attenuated bacterial vaccine based on
the salmonella typhi Ty21a carrier strain
x2
Dual-Antigens may offer lower likelihood of evolution of resistant viral mutants
Potential application across multiple coronavirus types, including COVID-19 (SARS-CoV-2)
Orally active live-attenuated bacterial vaccine based on
the salmonella typhi Ty21a carrier strain
x2
Dual-Antigens may offer lower likelihood of evolution of resistant viral mutants
We are currently conducting pre-clinical research on a potential oral vaccine for COVID-19 which leverages the bacterium Salmonella Typhi Ty21a which has been engineered to express and secrete two coronavirus antigens fused to an immunological adjuvant peptide. The specific bacterial vector strain is being designed with the goal to enable oral application and release of the proteins into the gut system to stimulate (through M-cells) mucosal and systemic immunity.
~2°C - 8°C
Potential to be
temperature stable
Salmonella Typhi Ty21a carrier strain has been safely used in more than 150 million administered doses worldwide
Developed at leading research and teaching university,
Julius-Maximilians-University Wuerzburg
COVID-19 (SARS-CoV-2)
COVID-19 is the disease caused by a new coronavirus called SARS-CoV-2 and was first reported in December 2019 in Wuhan, Hubei province, China. Most people infected with the COVID-19 virus will experience mild to moderate respiratory illness and recover without requiring special treatment. Older people, and those with underlying medical problems like cardiovascular disease, diabetes, chronic respiratory disease, and cancer are more likely to develop a serious illness.